Tuberculosis - Pipeline Review, H1 2020

May 2020 | 405 pages | ID: T933ED09586EN
Global Markets Direct

Abstracts

Tuberculosis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis – Pipeline Review, H1 2020, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 12, 8, 1, 59, 39 and 4 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4, 6, 35 and 34 molecules, respectively.

Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Tuberculosis - Overview
Tuberculosis - Therapeutics Development
Tuberculosis - Therapeutics Assessment
Tuberculosis - Companies Involved in Therapeutics Development
Tuberculosis - Drug Profiles
Tuberculosis - Dormant Projects
Tuberculosis - Discontinued Products
Tuberculosis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Tuberculosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Tuberculosis - Pipeline by Abera Bioscience AB, H1 2020
Tuberculosis - Pipeline by AGILeBiotics BV, H1 2020
Tuberculosis - Pipeline by Akshaya Bio Inc, H1 2020
Tuberculosis - Dormant Projects, H1 2020
Tuberculosis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Tuberculosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Abera Bioscience AB
AGILeBiotics BV
Akshaya Bio Inc
AN2 Therapeutics Inc
Archivel Farma SL
AstraZeneca Plc
Austrianni GmbH
BioLingus AG
BioNTech SE
Bioversys AG
Bristol-Myers Squibb Co
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
Collaborations Pharmaceuticals Inc
Consegna Pharma Inc
Crestone Inc
Daiichi Sankyo Co Ltd
Demuris Ltd
Eisai Co Ltd
Eli Lilly and Co
Ena Therapeutics Pty Ltd
Enyo Pharma SA
EpiVax Inc
Evotec SE
Faron Pharmaceuticals Oy
Gamaleya Federal Research Center of Epidemiology and Microbiology
GangaGen Inc
GC Pharma
GlaxoSmithKline Plc
Globeimmune Inc
Greffex Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
HanaVax Inc
Hsiri Therapeutics LLC
Immodulon Therapeutics Ltd
Immunitor Inc
ImmunoBiology Ltd
Innovare R & D SA De CV
Johnson & Johnson
Kolmar Pharma Co Ltd
L2 Diagnostics LLC
LegoChem Biosciences Inc
Matinas BioPharma Holdings Inc
Merck & Co Inc
MetalloPharm LLC
Microbiotix Inc
Mycosynthetix Inc
Nearmedic Plus Ltd
Novartis AG
NovoBiotic Pharmaceuticals LLC
NTxBio LLC
Opal Biosciences Ltd
Otsuka Holdings Co Ltd
Otsuka Pharmaceutical Co Ltd
Pai Life Sciences Inc
Palisades Therapeutics
Pathens Inc
PDS Biotechnology Corp
PeptiDream Inc
Pfizer Inc
Pharmapraxis
ProCrysta Biologix Inc
Qrumpharma Inc
Quratis Inc
QureTech Bio AB
Qurient Co Ltd
Sanofi
Sequella Inc
Serum Institute of India Ltd
Shanghai H&G Biotech
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
Sphaera Pharma Pte Ltd
Takeda Pharmaceutical Co Ltd
Target Medicals LLC
TB-Stopper
TenNor Therapeutics Ltd
The Broad Institute Inc
Theravectys SA
TVAX Biomedical Inc
Tydock Pharma Srl
Vaccibody AS
Vaxil Bio Therapeutics Ltd
Vaxinano SE
Vaxine Pty Ltd
Vaxxit Srl
Vichem Chemie Research Ltd
Vir Biotechnology Inc
Zata Pharmaceuticals Inc